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COST-EFFECTIVENESS OF EPLERENONE COMPARED WITH 
SPIRONOLACTONE IN PATIENTS WITH HEART FAILURE AFTER 
ACUTE MYOCARDIAL INFARCTION
Inês M1, Soares M2, Vitorino R1
1Pﬁ zer Portugal, Porto Salvo, Oeiras, Portugal; 2University of York, York, Yorkshire, UK
OBJECTIVES: Aldosterone blockers (AB) are recommended for use in heart failure 
(HF) and HF post acute myocardial infarction (AMI) in patients with left ventricular 
dysfunction. Although only eplerenone is licensed for post-AMI HF treatment, less 
expensive spironolactone is used in some clinical settings. This study aims to evaluate 
cost-effectiveness of eplerenone compared with spironolactone in Portuguese patients 
with HF post-AMI. METHODS: A Markov model was developed to predict life-years 
(LY), quality adjusted life-years (QALY) and associated costs of AB treatment over 
patients life time. Estimates of all cause mortality relative risks were obtained via a 
meta-regression of AB published trials. Transition probabilities were derived from 
EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Survival 
Study), adjusted by a Weibull function with meta-regression estimates. AB adverse 
events (hyperkalemia, gynescomatia) rates were derived from a published meta-anal-
ysis. AB class effect was assumed regarding non-fatal hospitalization rates. Resource 
use and discontinuation rates were elicited through a panel of six cardiologists with 
extensive clinical experience. Unit costs and other cause mortality rate were extracted 
from Portuguese ofﬁ cial sources. Utilities were obtained using a regression model 
published in the literature derived from EPHESUS EQ-5D data. Societal perspective 
was adopted and both costs and effectiveness were discounted at 5%. RESULTS: 
Average cost per patient for eplerenone and spironolactone treatment were c25,907 
and c20,963, respectively. Average effectiveness gained with eplerenone was 0.44LY 
and 0.41QALY, meaning the incremental cost-effectiveness ratios were c11,309/LY 
and c12,040/QALY. Although indirect comparison of eplerenone with spironolactone 
introduces some uncertainty for relative effectiveness and cost-effectiveness: probabi-
listic sensitivity analysis revealed eplerenone to be cost-effective in 59% of Monte 
Carlo iterations at a willingness to pay of c35,000/QALY. CONCLUSIONS: Com-
pared with spironolactone, eplerenone treatment in patients with HF post-AMI is 
effective in reducing mortality, improving quality of life and is cost-effective by com-
monly used criteria in Portugal.
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COST SAVINGS OF ENOXAPARIN OVER UFH IN MEDICAL PATIENTS 
IN CANADIAN HOSPITAL SETTING
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OBJECTIVES: Enoxaparin, a low molecular weight heparin, was approved for use in 
medical patients in Canada in 2001, however, its use in hospitals has been relatively 
low. Low utilization is thought to be due to the perception by hospital administration 
of increased drug costs when compared to unfractionated heparin (UFH). Examination 
of the cost of clinical events for thromboprophylaxis has demonstrated that enoxapa-
rin may be cost savings. METHODS: A decision tree model was developed to the 
compare clinical results of four thromboprophylaxis regimens: enoxaparin 40 mg once 
daily, UFH 5000 International Units (IU) twice daily, UFH 5,000 IU three times daily 
and no prophylaxis. The main clinical outcomes in the model included DVT, PE, major 
bleeds, heparin-induced thrombocytopenia and death and were based on published 
literature Recurrences of the ﬁ rst four endpoints were also modelled. Canadian treat-
ment pattern data was based on one academic institution in Toronto, Canada. Costing 
(2010 Canadian $) for each state was also developed for direct medical costs. Within 
the model, parameters such as cost of thromboprophylaxis, number of patients, duration 
of treatment, length of stay, among many other variables were varied to reﬂ ect a hospital 
speciﬁ c analysis. RESULTS: When combining clinical and economic data in a Cana-
dian hospital setting, use of enoxaparin was cost-saving in a majority of situations. 
In the reference case, a typical hospital setting switching from UFH to enoxaparin 
resulted in an overall cost savings to the hospital, wherein a population of 1000 annual 
medical patients would realize a savings of $90,000CAD. Sensitivity analysis showed 
that enoxaparin was not cost savings when medically ill patients did not receive any 
thromboprophylaxis. CONCLUSIONS: Enoxaparin is a clinically safe and efﬁ cacious 
thromboprophylaxis regimen in medically ill patients. The model and follow-up analysis 
demonstrate that it is also a cost-saving choice of thromboprophylaxis within the 
Canadian hospital setting.
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IS COREVALVE A COST-EFFECTIVE TREATMENT FOR PATIENTS WITH 
SEVERE AORTIC STENOSIS WHO SATISY ALL THE CRITERIA FOR 
CONVENTIONAL AORTIC VALVE REPLACEMENT?
Eaton JN, Mealing S, Watt M, Sculpher M
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OBJECTIVES: Aortic Stenosis (AS) is a severe cardiovascular condition; the treatment 
of which involves open surgery and cardiopulmonary bypass to replace the damaged 
aortic valve (AVR). AVR is invasive and carries a signiﬁ cant risk for patients with a 
high risk of perioperative mortality. Transcatheter aortic valve implantation using 
“CoreValve,” is less invasive, allowing for the percutaneous implantation of a replace-
ment valve in this patient group. However, the acquisition cost of CoreValve is greater 
than AVR, therefore it is important to assess whether CoreValve is a cost-effective 
alternative. METHODS: A 20-year Markov model was developed in Microsoft Excel. 
Treatment options were CoreValve and AVR with parameters derived from published 
literature. Both products were assumed to have the same long term impact on mortal-
ity. All costs were taken from the most recent published sources. Decrements were 
applied to age-speciﬁ c EQ-5D population norms to generate QALYs. Extensive proba-
bilistic and deterministic sensitivity analyses were performed to identify key cost-
effectiveness drivers. All costs and beneﬁ ts were discounted at 3.5% p.a. RESULTS: 
The model was very sensitive to changes in the short-term relative risk (RR) of mortal-
ity. In the base-case a short term RR of 0.57 was estimated from the available litera-
ture, the ICER was £25,229. However, the short-term mortality estimate for AVR 
was highly uncertain. Assuming a 0.75 RR the ICER is £34,603 and at 1.0 the ICER 
is £81,011. The model was also highly sensitive to changes in long term RR, device 
cost and time horizon. Assuming a threshold value of £30,000 per QALY gained, the 
probability that CoreValve is cost-effective is 0.54. CONCLUSIONS: Assuming that 
the RR of short-term mortality is at least 0.67 CoreValve is a cost-effective alternative 
for the treatment of severe AS in high risk patients.
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OBJECTIVES: Although statins are the mainstay of cholesterol management in Scot-
land, there remains a group of patients who are ineligible for such treatment due to 
contraindication or intolerance. This analysis estimates the cost-effectiveness of 
extended-release nicotinic acid/laropiprant 2 g/40 mg (ERN/LRPT), versus ezetimibe 
10 mg, as monotherapy for the treatment of mixed dyslipidaemia in Scotland in 
patients not currently receiving statin therapy. METHODS: The analysis was based 
on a previously published Markov model. Risk equations, based on the Framingham 
Heart Study, were used to model CHD-event rates in patients with established CHD, 
diabetes mellitus (DM) or a 10-year CHD-risk ≥20%. The model was run on a cohort 
of 2976 patient proﬁ les extracted from the General Practice Research Database. All 
patients had abnormalities in low-density-lipoprotein cholesterol (LDL-C ≥ 
2.0 mmol/L), high-density-lipoprotein cholesterol (HDL-C < 1.0 mmol/L [men], 
1.2 mmol/L [women]) and triglycerides (TG > 1.7 mmol/L). ERN/LRPT efﬁ cacy data 
were taken from the results of a published clinical trial, and ezetimibe data taken from 
a meta-analysis of monotherapy trials. Results were reported as the cost per quality-
adjusted life-year (QALY) gained. RESULTS: When compared to the use of ezetimibe, 
ERN/LRPT led to an increase in both QALYs and costs across the three patient-risk 
sub-groups. In patients with CHD, the base-case analysis estimated an incremental 
cost-effectiveness ratio (ICER) of £7559. Base-case results in patients with DM and 
patients facing a 10-year CHD risk ≥20% were £9,361 and £11,980, respectively. 
ICERS in the majority of sensitivity analyses did not vary by more than +/− £3000 
from the base case. CONCLUSIONS: When compared to ezetimibe, ERN/LRPT is 
projected to be cost-effective for the management of lipids in patients for whom the 
addition of statin is inappropriate or not tolerated, as reﬂ ected in the guidance issued 
by the Scottish Medicines Consortium.
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OBJECTIVES: The ACCOMPLISH trial demonstrated that an ACEi/CCB combina-
tion (benazepril/ amlodipine) signiﬁ cantly reduced cardiovascular events in high risk 
hypertension patients compared to an ACEi/HCTZ combination (benazepril/ hydro-
chlorothiazide). ACCOMPLISH trial was the ﬁ rst to compare ﬁ xed dose combination 
therapies and examine longer term outcomes in this patient population. This study 
evaluated health and economic outcomes based on robust ﬁ ndings from ACCOM-
PLISH, and extended this analysis to an ARB/CCB combination (valsartan /amlodip-
ine). METHODS: ACCOMPLISH evaluated over 11,500 patients with hypertension 
at high risk for cardiovascular events. Trial data on cardiovascular events, diabetes, 
and renal failure endpoints, compliance and dosing levels were used to populate a 
compartmental cohort model which followed patients over 4 years. Cost data from 
Sweden (reported in 2008 Euros) were assigned to acute events and follow-up care, 
as well as hypertension-related treatment. a dose equivalency analysis of valsartan and 
benazepril was used to assign appropriate drug costs for the extension of the analyses 
to valsartan/amlodipine. The daily cost of benazepril/hydrochlorothiazide was c0.21, 
c0.16 for benazepril/amlodipine, and ranged between c0.90 and c1.10 for valsartan/
amlodipine, depending on dose. All outcomes were discounted at 3% per annum. 
RESULTS: Total costs over 4 years averaged c4554 per patient on benazepril/hydro-
cholorothiazide. With a lower drug cost and 45 fewer acute events per 1000 treated 
patients, costs were c322 lower per patient on benazepril/amlodipine. Assuming same 
outcome as for benazepril/amlodipine, valsartan/amlodipine was associated with 
incremental drug costs of c963 per patient, and c693 in overall costs, resulting in a 
cost per event avoided of c15,543. CONCLUSIONS: Based on the results of ACCOM-
PLISH, the combination of benzepril/amlodipine is clearly preferable to benazepril/
